Spain pledges to pay pharma back this year; Mylan gets final nod for Agila buy; AZ gets nod for new plant;

@FiercePharma: India approves $1.6bn acquisition of Agila Specialties by Mylan. More | Follow @FiercePharma

@EricPFierce: ICYMI: Indian regulators find no serious problems at Wockhardt plant banned by FDA. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: How a peptide and a protein can help predict heart attack--and ease overcrowding in the emergency room. More from FierceBiomarkers | Follow @CarlyHFierce

> Spanish officials say they've instituted a new payment plan aimed at paying off pharma-related debt by the end of the year. Report

> India's government has given the final go-ahead to U.S.-based Mylan's ($MYL) $1.6 billion buyout of Agila Specialties, the injectable drugs unit of India-based Strides Arcolab. Report

> AstraZeneca ($AZN) won local planning approval for a new plant in Hurdsfield, England, where the expansion may create 36 new jobs. Report

> The U.K.'s top cost-effectiveness watchdog challenged the notion that the National Institute for Health and Care Excellence (NICE) is quashing innovation. Report

> Takeda Pharmaceuticals sued Par Pharmaceutical for the second time over Par's plans to knock off Takeda's gout drug Colcrys. Report

> More patients continued taking a four-in-one cardiovascular drug than the individual meds it replaced, with the effect especially pronounced in patients with historical problems sticking to their drugs regimens, a study found. Report

Medical Device News

@FierceMedDev: "Brain window" implant could enable targeted treatments. Item | Follow @FierceMedDev

@MarkHFierce: bioMerieux's $450M BioFire Dx buy gives it an even greater foothold in infectious disease diagnostics. Story | Follow @MarkHFierce

> Johns Hopkins: Robotic surgery complications grossly underreported. More

> Bard embraces urology home care with $262M Rochester Medical bid. Article

> Biomet metal hip lawsuit to proceed. News

Biotech News

@FierceBiotech: AstraZeneca rolls the dice (again) on a failed cancer drug. More | Follow @FierceBiotech

@JohnCFierce: Be sure to check out our new weekly report: FierceDiagnostics | Follow @JohnCFierce

@RyanMFierce: Rare diabetes drug development startup Elcelyx Tx spins off nutraceutical assets into NaZura BioHealth. Release | Follow @RyanMFierce

@EmilyMFierce: Altered gene in mice extends lifespan by 20%. Story | Follow @EmilyMFierce

> Pursuing Alzheimer's, iPierian grabs $30M and spins off orphan drug biotech. More

> Transgene, Jennerex ponder fate of tumor-fighting virus after PhIIb failure. Story

> Rockwell Medical surges on more promising PhIII data for iron-delivery drug. Article

> BioMérieux to fork over $450M for Utah Dx outfit. News

Drug Delivery News

@MichaelGFierce: Self-powered nanomeds deliver bone-strengthening drugs. Article | Follow @MichaelGFierce

> Oramed submits pre-IND for oral exenatide Type 2 diabetes pill. More

> Meda buys Acton for $135M+, snags asthma inhaler. Item

> Google invests in oral drug delivery for insulin, other biologics. Story

> Nanosized DNA cages could deliver drugs with triggered release. Report

> Novan collects $7.8 million from gov to develop nitric oxide burn med. News

Diagnostics News

> BioFire Diagnostics keeps identity in $450M bioMérieux deal. Story

> Indian Dx giant emerges. Article

> ITC, Accumetrics merge with eye on global cardiovascular Dx. News

> Study: PET/MRI combo adds heft in cancer Dx. Report

> Cepheid wins key 'moderate complexity' designation for combo TB test. More

> Siemens co-develops Alzheimer's blood test. Item

Biomarkers News

> Biomarker sorely needed for diagnosing chronic migraines. Story

> Heart attack biomarker could ease ER crowding. News

> Researchers zero in on biomarker for early diagnosis of ovarian cancer. Report

> Blood test flags organ transplant injury. Item

> Study: Protein may predict mesothelioma survival. More

> Biomarker test boosts prospects for Parkinson's prediction. Article

And Finally... Younger generations aren't seeing the same gains in cardiovascular health as the elderly, the Centers for Disease Control and Prevention (CDC) said. Report

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.